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Although newer rapid influenza tests have improved our ability to rule out disease,
they are still better at ruling in influenza. Change in management should be
considered before testing.DS
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*Pooled estimates.Of the 162 studies included for full-
text review, 38 were excluded for
not reporting influenza A and B
results separately, leaving 124 articles
for quantitative analysis. Overall, the
new rapid influenza tests, digital
immunoassays, and rapid nucleic
acid amplification tests demonstrated
strikingly higher sensitivities for
influenza A and B comparedwith the
more traditional rapid influenza diag-
nostic tests. The pooled sensitivities
varied widely between test types
(ranging from 53% to 95%), whereas
the pooled specificities were consis-
tently greater than 98.3%.
In assessment of risk of bias ac-
cording to the Quality Assessmentof Diagnostic Accuracy Studies,1
more than half of studies
involving rapid influenza
diagnostic tests and rapid nucleic
acid amplification tests had
selection bias or were at high
risk of bias. Analysis suggests that
bias could have been introduced
through lack of blinding to the
reference test (with the highest
risk of bias in the non automated
rapid influenza diagnostic tests,
and differences in other covariates
(ie, industry sponsorship, point-of-
care testing, and commercial
brand). Although the heterogene-
ity identified in rapid test sensi-
tivity could not be fully explained
by underreporting of clinicaly Medicine 1
tests, authors calculated sensitivity,
specificity, and positive and
negative likelihood ratios (LRs) with
95% confidence intervals. Influenza
A and B were considered
separately. For meta-analysis,
Bayesian bivariate random-effects
models were used to generate
pooled sensitivity, specificity, and
LR estimates with 95% credible
intervals. Forest plots and
hierarchic summary receiver
operating characteristic curves
were created, and stratified
analyses (eg, age, symptom
duration, commercial brand, virus
subtype) were done to further
examine heterogeneity.
Systematic Review Snapshotcovariates, subgroup analysis
revealed that pooled sensitivities
favored children over adults by
12.1% to 31.8% and favored in-
dustry sponsorship by 6.2% to
34.0%. Sensitivity analysis did not
change the main findings.
Commentary
For the 2015 to 2016 season, the
Centers for Disease Control and
Prevention estimated that influenza
resulted in 25 million illnesses,
310,000 hospitalizations, and
12,000 deaths and predict that the
2017 to 2018 season will be more
severe.2,3 Although influenza affects
all populations, those at highest risk
for serious outcomes include
patients at extremes of age, those
with chronic medical conditions,
immunosuppression, and pregnant
patients.4 Influenza symptoms are
nonspecific; therefore, having a
more accurate diagnostic test could
improve patient outcomes by
facilitating timely antiviral initiation
to high-risk populations while
potentially decreasing antibiotic
overuse. In addition, early
identification or ruling out of2 Annals of Emergency Medicineinfluenza could facilitate
throughput and admission
processes while also using isolation
space appropriately.
A previous 2012 systematic review
examined only traditional rapid
influenza diagnostic tests and re-
ported excellent specificity of
98.2%, but poor sensitivity of only
62.3%, indicating these tests could
be used to rule in influenza but not
exclude the diagnosis.5 This
updated review examines the
diagnostic accuracy of 2 newer
types of rapid influenza tests
(digital immunoassays and rapid
nucleic acid amplification tests) in
addition to the traditional rapid
influenza diagnostic tests. Similar to
the rapid influenza diagnostic tests,
the newer tests can be performed
rapidly at the point of care, and do
not require laboratory personnel to
operate. The key finding was that
digital immunoassays and rapid
nucleic acid amplification tests
offer markedly higher sensitivities
(ranging from 76.8% to 95.4%),
with similarly high specificities
(>98%). The rapid nucleic acid
amplification tests had an overall
negative LR less than 0.1, making
them the only test that could
usefully rule out influenza;
however, performance varied
widely among different
commercial assays, making this
finding inconclusive. The authors
of this systematic review reported
that the rapid nucleic acid
amplification tests cost 2 to 5 times
more than the rapid influenza
diagnostic tests or digital
immunoassays.
Current guidelines from the Cen-
ters for Disease Control and Pre-
vention recommend testing
patients for influenza only if test
results would change clinicalmanagement or if patients are be-
ing admitted to the hospital.6
Therefore, clinicians should use
the newer rapid influenza
diagnostic tests in the context of
each patient encounter,
understanding that although the
newer tests have improved the
ability to rule out disease, they
are still better at ruling in disease.
Before a local influenza epidemic
has been identified, given the
extremely high positive LR, rapid
diagnostic testing would rule in
disease when results were
positive. Once the local health
department has announced the
onset of an epidemic, routine
diagnostic testing for influenza
may not be required and empiric
treatment could be considered
for high-risk populations.
The findings should be interpreted
with caution because of the risk of
bias introduced by industry spon-
sorship. The majority of the digital
immunoassay (68%) and rapid
nucleic acid amplification test
(62%) studies were sponsored by
industry, and a sensitivity analysis
found that industry sponsorship
was associated with higher sensi-
tivities. Of note, the systematic
review itself was funded in part by
a rapid influenza test company.
The medical literature is clear that
industry-sponsored research tends
to favor the industry’s product and
affects how physicians practice
medicine; therefore, further
research on rapid tests is
warranted.7,8
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